IL1RL1 and experimental autoimmune encephalomyelitis: In fact, among other CNS pathologies, Jiang et al. [20] demonstrated that IL-33 administered after experimental autoimmune encephalomyelitis (EAE) onset could be protective against the disease and also that ST2−/− mice developed exacerbated disease following EAE induction.